Insights into the comorbidity between type 2 diabetes and osteoarthritis.

Multimorbidity is a rising public health challenge with important implications for health management and policy. The most common multimorbidity pattern is for the combination of cardiometabolic and osteoarticular diseases. Here, we study the genetic underpinning of the comorbidity between type 2 diabetes and osteoarthritis. We find genome-wide genetic correlation between the two diseases, and robust evidence for association signal colocalization at 18 genomic regions. We integrate multi-omics and functional information to resolve the colocalizing signals, and identify high-confidence effector genes, including FTO and IRX3, which provide proof-of-concept insights into the epidemiologic link between obesity and both diseases. We find enrichment for lipid metabolism and skeletal formation pathways for signals underpinning the knee and hip osteoarthritis comorbidities with type 2 diabetes, respectively. Causal inference analysis identifies complex effects of tissue-specific gene expression on comorbidity outcomes. Our findings provide insights into the biological basis for the type 2 diabetes-osteoarthritis disease co-occurrence.

[1]  E. McDonagh,et al.  Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs , 2022, Nature Reviews Drug Discovery.

[2]  E. Zeggini,et al.  A molecular map of long non-coding RNA expression, isoform switching and alternative splicing in osteoarthritis , 2022, Human molecular genetics.

[3]  G. Davey Smith,et al.  Harnessing tissue-specific genetic variation to dissect putative causal pathways between body mass index and cardiometabolic phenotypes. , 2022, American journal of human genetics.

[4]  Tom R. Gaunt,et al.  Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations , 2021, Cell.

[5]  J. V. van Meurs,et al.  Using multivariable Mendelian randomization to estimate the causal effect of bone mineral density on osteoarthritis risk, independently of body mass index , 2021, medRxiv.

[6]  E. Zeggini,et al.  A molecular quantitative trait locus map for osteoarthritis , 2021, Nature Communications.

[7]  A. Espelt,et al.  Multimorbidity and its associated factors among adults aged 50 and over: A cross-sectional study in 17 European countries , 2021, PloS one.

[8]  E. Bonifacio,et al.  Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories toward type 2 diabetes , 2020, bioRxiv.

[9]  Stephen Burgess,et al.  A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits , 2019, Nature Communications.

[10]  Yoshiya Tanaka,et al.  Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. , 2020, Rheumatology.

[11]  A. Martín-Montalvo,et al.  Thyroid hormones in diabetes, cancer, and aging , 2020, Aging cell.

[12]  J. Frias Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes , 2020, Expert review of endocrinology & metabolism.

[13]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[14]  Stephen C. J. Parker,et al.  Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D , 2020, Nature Communications.

[15]  Y. Leung,et al.  Diabetes mellitus is not a risk factor for osteoarthritis , 2020, RMD Open.

[16]  J. Aronson,et al.  Naltrexone-bupropion (Mysimba®) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. , 2020, British journal of clinical pharmacology.

[17]  M. Abney,et al.  Genome-Wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2. , 2019, American journal of human genetics.

[18]  C. Cooper,et al.  Type 2 diabetes mellitus and osteoarthritis. , 2019, Seminars in arthritis and rheumatism.

[19]  M. Prince,et al.  Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies , 2019, Journal of comorbidity.

[20]  P. Raina,et al.  Multimorbidity and comorbidity revisited: refining the concepts for international health research. , 2019, Journal of clinical epidemiology.

[21]  C. Helmick,et al.  Prevalence of Arthritis Among Adults with Prediabetes and Arthritis-Specific Barriers to Important Interventions for Prediabetes — United States, 2009–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[22]  Anthony J. Payne,et al.  Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps , 2018, Nature Genetics.

[23]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[24]  Samuel E. Jones,et al.  Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry , 2018, bioRxiv.

[25]  P. Visscher,et al.  Meta-analysis of genome-wide association studies for height and body mass index in ∼700,000 individuals of European ancestry , 2018, bioRxiv.

[26]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[27]  Kari Stefansson,et al.  Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis , 2018, Nature Genetics.

[28]  Giovanni Malerba,et al.  Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes , 2017, Nature Genetics.

[29]  F. Cantatore,et al.  Osteoblast role in osteoarthritis pathogenesis , 2017, Journal of cellular physiology.

[30]  John P. Overington,et al.  The druggable genome and support for target identification and validation in drug development , 2016, Science Translational Medicine.

[31]  T. Jin Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in Glucose Homeostasis. , 2016, Endocrine reviews.

[32]  B. Alman,et al.  Hedgehog inhibits β-catenin activity in synovial joint development and osteoarthritis. , 2016, The Journal of clinical investigation.

[33]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[34]  Emma Ahlqvist,et al.  Identification of novel genes for glucose metabolism based upon expression pattern in human islets and effect on insulin secretion and glycemia. , 2015, Human molecular genetics.

[35]  M. Daly,et al.  LD Score regression distinguishes confounding from polygenicity in genome-wide association studies , 2014, Nature Genetics.

[36]  A. Gelber,et al.  Osteoarthritis , 2020, Annals of Internal Medicine.

[37]  N. Cox,et al.  Obesity-associated variants within FTO form long-range functional connections with IRX3 , 2014, Nature.

[38]  Tom S. Price,et al.  Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. , 2014, American journal of human genetics.

[39]  C. Wallace,et al.  Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics , 2013, PLoS genetics.

[40]  B. Olsen,et al.  Osteoblast–adipocyte lineage plasticity in tissue development, maintenance and pathology , 2014, Cellular and Molecular Life Sciences.

[41]  T. Kanamoto,et al.  OBIF, an osteoblast induction factor, plays an essential role in bone formation in association with osteoblastogenesis , 2012, Development, growth & differentiation.

[42]  G. Davey Smith,et al.  Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. , 2012, International journal of epidemiology.

[43]  Ralf Herwig,et al.  ConsensusPathDB: toward a more complete picture of cell biology , 2010, Nucleic Acids Res..

[44]  W. B. van den Berg,et al.  To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. , 2010, Current drug targets.

[45]  L. Ray,et al.  Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. , 2010, CNS & neurological disorders drug targets.

[46]  Philippe Froguel,et al.  Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. , 2009, American journal of human genetics.

[47]  Jonathan A C Sterne,et al.  The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. , 2007, American journal of epidemiology.

[48]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[49]  D. Payan,et al.  R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[50]  S. Norby [Mendelian randomization]. , 2005, Ugeskrift for laeger.

[51]  Gideon A. Rodan,et al.  Control of osteoblast function and regulation of bone mass , 2003, Nature.